pep005 and Head-and-Neck-Neoplasms

pep005 has been researched along with Head-and-Neck-Neoplasms* in 2 studies

Trials

1 trial(s) available for pep005 and Head-and-Neck-Neoplasms

Article	Year
Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit. Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:3 Topics: Aged; Aged, 80 and over; Diterpenes; Facial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hutchinson's Melanotic Freckle; Male; Middle Aged; Prospective Studies; Scalp; Skin Neoplasms; Treatment Outcome	2020

Article

Year

Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit.

Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:3

Topics: Aged; Aged, 80 and over; Diterpenes; Facial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hutchinson's Melanotic Freckle; Male; Middle Aged; Prospective Studies; Scalp; Skin Neoplasms; Treatment Outcome

2020

Other Studies

1 other study(ies) available for pep005 and Head-and-Neck-Neoplasms

Article	Year
Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of two cases. The British journal of dermatology, 2015, Volume: 173, Issue:6 Actinic keratoses (AKs) are defined as cutaneous areas of atypical squamous transformation that are regarded as an early step in the continuum of alterations leading from normal skin to invasive and metastatic squamous cell carcinoma (SCC). AKs are classified as precancerous lesions by some authors and in situ SCC by others. The rate of evolution of a given AK to an invasive SCC has been estimated as 0·075-0·096% per lesion per year. These rates are similar to those estimated for gynaecological intraepithelial neoplasia. We describe two cases of SCC with rapid onset that developed after the application of ingenol mebutate gel for the treatment of AKs. Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dermatologic Agents; Diterpenes; Drug Eruptions; Facial Dermatoses; Facial Neoplasms; Female; Head and Neck Neoplasms; Humans; Keratosis, Actinic; Skin Neoplasms	2015

Article

Year

Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of two cases.

The British journal of dermatology, 2015, Volume: 173, Issue:6

Actinic keratoses (AKs) are defined as cutaneous areas of atypical squamous transformation that are regarded as an early step in the continuum of alterations leading from normal skin to invasive and metastatic squamous cell carcinoma (SCC). AKs are classified as precancerous lesions by some authors and in situ SCC by others. The rate of evolution of a given AK to an invasive SCC has been estimated as 0·075-0·096% per lesion per year. These rates are similar to those estimated for gynaecological intraepithelial neoplasia. We describe two cases of SCC with rapid onset that developed after the application of ingenol mebutate gel for the treatment of AKs.

Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dermatologic Agents; Diterpenes; Drug Eruptions; Facial Dermatoses; Facial Neoplasms; Female; Head and Neck Neoplasms; Humans; Keratosis, Actinic; Skin Neoplasms

2015